Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2368-2374

  Mehta, Jyotsna ^a   Wang, Hongwei ^a   Fryzek, Jon P ^b   Iqbal, Sheikh Usman ^a   Mesa, Ruben ^c  

^a Departments of Clinical Development and Medical Affairs   (United States)

^b EpidStat Institute   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Health resource utilization; Myeloproliferative disorders

Indexed keywords

PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; COMORBIDITY; COST OF ILLNESS; DISEASE COURSE; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; OBSERVATIONAL STUDY; OUTPATIENT CARE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; UNITED STATES; YOUNG ADULT; ADOLESCENT; CHILD; FACTUAL DATABASE; HEALTH CARE PLANNING; MYELOPROLIFERATIVE DISORDERS; PATIENT ATTITUDE; RETROSPECTIVE STUDY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84925326065     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.879127     Document Type: Article

References (27)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097.
2. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-683.
3. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF):an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-1203.
4. Rupoli S, Da Lio L, Sisti S, et al. Primary myelofibrosis:a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994;68:205-212.
5. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF):international prospective validation and reliability trial in 402 patients. Blood 2011;118:401-408.
6. Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria:a population-based study. Haematologica 2009;94:865-869.
7. Johansson P, Kutti J, Andreasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med 2004;256:161-165.
8. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001;49:164-166.
9. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia:an Olmsted county study, 1976-1995. Am J Hematol 1999;61:10-15.
10. Ridell B, Carneskog J, Wedel H, et al. Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur J Haematol 2001;65:267-271.
11. Phekoo KJ, Richards MA, Moller H, et al. Th e incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91:1400-1404.
12. Prochazka AV, Markowe HL. Th e epidemiology of polycythaemia rubra vera in England and Wales 1968-1982. Br J Cancer 1986;53: 59-64.
13. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
14. Ana BJ, Suman VJ, Sobell JL, et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 2006;47:89-93.
15. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992;48:20-26.
16. Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2002;65:132-139.
17. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders:incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993;189:121-132.
18. Policitemia GIS. Polycythemia vera:the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123: 656-664.
19. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
20. Myeloproliferative Disorders Research Consortium. What are myeloproliferative disorders. Available from:www.mpd-rc.org/ readarticle.php?article-id=1
21. Zimmerman MP, Mehr SR. Myeloproliferative disorders and myelofibrosis. Am J Manage Care 2012;18:1-3.
22. Hall SF. Auser's guide to selecting a comorbidity index for clinical research. J Clin Epidemiol 2006;59:849-855.
23. Yancik R, Ershler W, Satariano W, et al. Report of the national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci 2007;62:275-280.
24. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies:development and validation. J Chron Dis 1987;40:373-383.
25. Price GL, Pohl GM, Xie J, et al. A retrospective observational study of annual healthcare costs for patients with forms of myeloproliferative neoplasms (MPN). Blood 2011;118(Suppl. 1): Abstract 2060.
26. Karve S, Price GL, Davis KL, et al. Health care utilization and associated costs in elderly persons with non-CML myeloproliferative neoplasms:real-world evidence from a United States Medicare population. Blood 2012;120(Suppl. 1):Abstract 4273.
27. The Leukemia &Lymphoma Society. Myeloproliferative neoplasms. Available from:www.lls.org/diseaseinformation/ myeloproliferativediseases/